Disease on EC 3.5.1.108 - UDP-3-O-acyl-N-acetylglucosamine deacetylase
Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Acquired Immunodeficiency Syndrome
Chitosan, the deacetylated form of chitin, is necessary for cell wall integrity in Cryptococcus neoformans.
Acquired Immunodeficiency Syndrome
NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities.
Acute Kidney Injury
Porous Se@SiO2 nanospheres attenuate cisplatin-induced acute kidney injury via activation of Sirt1.
Acute Kidney Injury
SIRT1-mediated HMGB1 deacetylation suppresses sepsis-associated acute kidney injury.
Adenocarcinoma
Structural Insight into the Interactions between Structurally Similar Inhibitors and SIRT6.
Adenocarcinoma of Lung
Ampelopsin induces apoptosis by regulating multiple c-Myc/S-phase kinase-associated protein 2/F-box and WD repeat-containing protein 7/histone deacetylase 2 pathways in human lung adenocarcinoma cells.
Adenocarcinoma of Lung
Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients.
Adenocarcinoma of Lung
HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma.
Adrenoleukodystrophy
Targeting foam cell formation in inflammatory brain diseases by the histone modifier MS-275.
alpha-tubulin n-acetyltransferase deficiency
MEC-17 Deficiency Leads to Reduced ?-Tubulin Acetylation and Impaired Migration of Cortical Neurons.
Alzheimer Disease
A Label-free Sirtuin 1 Assay based on Droplet-Electrospray Ionization Mass Spectrometry.
Alzheimer Disease
Beneficial Effects of Sulforaphane Treatment in Alzheimer's Disease May Be Mediated through Reduced HDAC1/3 and Increased P75NTR Expression.
Alzheimer Disease
Clinical validation of the novel HDAC6 radiotracer [18F]EKZ-001 in the human brain.
Alzheimer Disease
Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction.
Alzheimer Disease
SIRT1 deacetylase activity and the maintenance of protein homeostasis in response to stress: an overview.
Alzheimer Disease
SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis.
Alzheimer Disease
Sirt1 overexpression in neurons promotes neurite outgrowth and cell survival through inhibition of the mTOR signaling.
Alzheimer Disease
Sirtuin 5: a review of structure, known inhibitors and clues for developing new inhibitors.
Amyotrophic Lateral Sclerosis
Clinical validation of the novel HDAC6 radiotracer [18F]EKZ-001 in the human brain.
Amyotrophic Lateral Sclerosis
Muscle histone deacetylase 4 upregulation in amyotrophic lateral sclerosis: potential role in reinnervation ability and disease progression.
Amyotrophic Lateral Sclerosis
SIRT1 deacetylase in aging-induced neuromuscular degeneration and amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis.
Arteriosclerosis
A new activator of esterase D decreases blood cholesterol level through ESD/JAB1/ABCA1 pathway.
Arthritis
Implication of the deacetylase sirtuin-1 on synovial angiogenesis and persistence of experimental arthritis.
Arthritis, Experimental
Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis.
Aspergillosis
Identification of a Key Lysine Residue in Heat Shock Protein 90 Required for Azole and Echinocandin Resistance in Aspergillus fumigatus.
Asthma
Histone acetylase and deacetylase activity in alveolar macrophages and blood mononocytes in asthma.
Astrocytoma
[Increased Egr-1 binding to promoter induced by histone hyperacetylation promotes gdnf gene transcription].
Ataxia Telangiectasia
Senataxin controls meiotic silencing through ATR activation and chromatin remodeling.
Atherosclerosis
Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice.
Atherosclerosis
Patient hiPSCs Identify Vascular Smooth Muscle Arylacetamide Deacetylase as Protective against Atherosclerosis.
Atherosclerosis
SIRT1 inhibits angiotensin II-induced vascular smooth muscle cell hypertrophy.
Atherosclerosis
SIRT1 regulates CD40 expression induced by TNF-? via NF-?B pathway in endothelial cells.
Atherosclerosis
SIRT1 suppresses PMA and ionomycin-induced ICAM-1 expression in endothelial cells.
Atherosclerosis
SIRT6 Protects Smooth Muscle Cells From Senescence and Reduces Atherosclerosis.
Atherosclerosis
The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression.
Autoimmune Diseases
Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis.
Autoimmune Diseases
Decreased SIRT1 expression in the peripheral blood of patients with Graves' disease.
Bacterial Infections
Active nuclear import of the deacetylase Sirtuin-2 is controlled by its C-terminus and importins.
Bone Resorption
Sirtuin 1 inhibits TNF-?-mediated osteoclastogenesis of bone marrow-derived macrophages through both ROS generation and TRPV1 activation.
Brain Ischemia
Resveratrol pretreatment protects rat brain from cerebral ischemic damage via a sirtuin 1-uncoupling protein 2 pathway.
Brain Ischemia
Targeted acetylation of NF-kappaB/RelA and histones by epigenetic drugs reduces post-ischemic brain injury in mice with an extended therapeutic window.
Breast Neoplasms
?-catenin deacetylation is essential for WNT-induced proliferation of breast cancer cells.
Breast Neoplasms
A Chimeric SERM-Histone Deacetylase Inhibitor Approach to Breast Cancer Therapy.
Breast Neoplasms
A positive role of DBC1 in PEA3-mediated progression of estrogen receptor-negative breast cancer.
Breast Neoplasms
Aberrant HDAC3 expression correlates with brain metastasis in breast cancer patients.
Breast Neoplasms
Amurensin G, a potent natural SIRT1 inhibitor, rescues doxorubicin responsiveness via down-regulation of multidrug resistance 1.
Breast Neoplasms
Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells.
Breast Neoplasms
Aromatase Acetylation Patterns and Altered Activity in Response to Sirtuin Inhibition.
Breast Neoplasms
ATAT1/MEC-17 acetyltransferase and HDAC6 deacetylase control a balance of acetylation of alpha-tubulin and cortactin and regulate MT1-MMP trafficking and breast tumor cell invasion.
Breast Neoplasms
Breaking down the Contradictory Roles of Histone Deacetylase SIRT1 in Human Breast Cancer.
Breast Neoplasms
c-Src/histone deacetylase 3 interaction is crucial for hepatocyte growth factor dependent decrease of CXCR4 expression in highly invasive breast tumor cells.
Breast Neoplasms
Checkpoint suppressor 1 suppresses transcriptional activity of ER? and breast cancer cell proliferation via deacetylase SIRT1.
Breast Neoplasms
Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells.
Breast Neoplasms
Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
Breast Neoplasms
Correction: Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor.
Breast Neoplasms
Deacetylase activity of human tumor cells producing immunosuppressive aminosugars: its possible role in resistance to cell-mediated cytotoxicity.
Breast Neoplasms
Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients.
Breast Neoplasms
Efficacy of Hybrid Vitamin D Receptor Agonist/Histone Deacetylase Inhibitors in Vitamin D-Resistant Triple-Negative 4T1 Breast Cancer.
Breast Neoplasms
Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor.
Breast Neoplasms
Expression of DBC1 is associated with nuclear grade and HER2 expression in breast cancer.
Breast Neoplasms
Identification of Sirtuin 3, a mitochondrial protein deacetylase, as a new contributor to tamoxifen resistance in breast cancer cells.
Breast Neoplasms
Increased stability of heterogeneous ribonucleoproteins by a deacetylase inhibitor.
Breast Neoplasms
Inhibition of sirtuin 1 deacetylase by miR-211-5p provides a mechanism for the induction of cell death in breast cancer cells.
Breast Neoplasms
Resveratrol-induced Sirt1 phosphorylation by LKB1 mediates mitochondrial metabolism.
Breast Neoplasms
Role of deleted in breast cancer 1 (DBC1) protein in SIRT1 deacetylase activation induced by protein kinase A and AMP-activated protein kinase.
Breast Neoplasms
SIRT1 Positively Regulates Breast Cancer Associated Human Aromatase (CYP19A1) Expression.
Breast Neoplasms
Sirt3 Exerts Its Tumor-Suppressive Role by Increasing p53 and Attenuating Response to Estrogen in MCF-7 Cells.
Breast Neoplasms
The pan-histone deacetylase inhibitor LBH589 (panobinostat) alters the invasive breast cancer cell phenotype.
Breast Neoplasms
The SIRT2 Deacetylase Stabilizes Slug to Control Malignancy of Basal-like Breast Cancer.
Breast Neoplasms
Transcriptional regulation of the transforming growth factor beta type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cells.
Breast Neoplasms
TWIST represses estrogen receptor-alpha expression by recruiting the NuRD protein complex in breast cancer cells.
Breast Neoplasms
[Mechanism of apoptosis induced by SIRT1 deacetylase inhibitors in human breast cancer MCF-7 drug-resistant cells]
Canavan Disease
Increasing N-acetylaspartate in the Brain during Postnatal Myelination Does Not Cause the CNS Pathologies of Canavan Disease.
Candidiasis
Discovery of Novel Fungal Lanosterol 14?-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis.
Carcinogenesis
Active nuclear import of the deacetylase Sirtuin-2 is controlled by its C-terminus and importins.
Carcinogenesis
AG1031 induces apoptosis through suppressing SIRT1/p53 pathway in human neuroblastoma cells.
Carcinogenesis
Breaking down the Contradictory Roles of Histone Deacetylase SIRT1 in Human Breast Cancer.
Carcinogenesis
Curcumin augments the efficacy of antitumor drugs used in leukemia by modulation of heat shock proteins via HDAC6.
Carcinogenesis
Depletion of sirtuin 1 (SIRT1) leads to epigenetic modifications of telomerase (TERT) gene in hepatocellular carcinoma cells.
Carcinogenesis
Discovery of a potent small molecule SIRT1/2 inhibitor with anticancer effects.
Carcinogenesis
DOC1-Dependent Recruitment of NURD Reveals Antagonism with SWI/SNF during Epithelial-Mesenchymal Transition in Oral Cancer Cells.
Carcinogenesis
Downregulation of Sirt1 by antisense oligonucleotides induces apoptosis and enhances radiation sensitization in A549 lung cancer cells.
Carcinogenesis
Enzymic deacetylation of carcinogenic arylacetamides by tissue microsomes of the dog and other species.
Carcinogenesis
EX527, a Sirt-1 inhibitor, induces apoptosis in glioma via activating the p53 signaling pathway.
Carcinogenesis
HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma.
Carcinogenesis
Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation.
Carcinogenesis
In Vitro Effect of the Histone Deacetylase Inhibitor Valproic Acid on Viability and Apoptosis of the PLC/PRF5 Human Hepatocellular Carcinoma Cell Line
Carcinogenesis
Infection Reveals a Modification of SIRT2 Critical for Chromatin Association.
Carcinogenesis
Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma.
Carcinogenesis
Lycopene metabolite, apo-10'-lycopenoic acid, inhibits diethylnitrosamine-initiated, high fat diet-promoted hepatic inflammation and tumorigenesis in mice.
Carcinogenesis
Modulating SIRT1 activity variously affects thymic lymphoma development in mice.
Carcinogenesis
N-acetylbenzidine and N,N'-diacetylbenzidine formation by rat and human liver slices exposed to benzidine.
Carcinogenesis
Regulation of Apoptosis and Radiation Sensitization in Lung Cancer Cells via the Sirt1/NF-?B/Smac Pathway.
Carcinogenesis
SIRT1 gene expression upon genotoxic damage is regulated by APE1 through nCaRE-promoter elements.
Carcinogenesis
SIRT1 inhibition by melatonin exerts antitumor activity in human osteosarcoma cells.
Carcinogenesis
SIRT1 Promotes Tumorigenesis and Resistance to Chemotherapy in Hepatocellular Carcinoma and its Expression Predicts Poor Prognosis.
Carcinogenesis
SIRT1 RNAi knockdown induces apoptosis and senescence, inhibits invasion and enhances chemosensitivity in pancreatic cancer cells.
Carcinogenesis
SIRT4 inhibits malignancy progression of NSCLCs, through mitochondrial dynamics mediated by the ERK-Drp1 pathway.
Carcinogenesis
SIRT4 inhibits the proliferation, migration, and invasion abilities of thyroid cancer cells by inhibiting glutamine metabolism.
Carcinogenesis
SIRT5 Promotes Cisplatin Resistance in Ovarian Cancer by Suppressing DNA Damage in a ROS-Dependent Manner via Regulation of the Nrf2/HO-1 Pathway.
Carcinogenesis
SIRT7 Regulates Lipopolysaccharide-Induced Inflammatory Injury by Suppressing the NF-?B Signaling Pathway.
Carcinogenesis
Sirtuin 1 Activation Suppresses the Growth of T-lymphoblastic Leukemia Cells by Inhibiting NOTCH and NF-?B Pathways.
Carcinogenesis
Sirtuin 2 mutations in human cancers impair its function in genome maintenance.
Carcinogenesis
Sirtuin-1 Regulates Acinar-to-Ductal Metaplasia and Supports Cancer Cell Viability in Pancreatic Cancer.
Carcinogenesis
Sirtuin-7 knockdown inhibits the growth of endometrial cancer cells by inducing apoptosis via the NF-?B signaling pathway.
Carcinogenesis
The Deacetylase SIRT1 Promotes Membrane Localization and Activation of Akt and PDK1 During Tumorigenesis and Cardiac Hypertrophy.
Carcinogenesis
The NAD-dependent deacetylase SIRT2 regulates T cell differentiation involved in tumor immune response.
Carcinogenesis
The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth.
Carcinogenesis
USP31 acetylation at Lys1264 is essential for its activity and cervical cancer cell growth.
Carcinoma
Bax, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma.
Carcinoma
Effect of trichostatin A on anti HepG2 liver carcinoma cells: inhibition of HDAC activity and activation of Wnt/?-Catenin signaling.
Carcinoma
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.
Carcinoma
Study of Antitumor Activity of Sodium Phenylbutyrate, Histon Deacetylase Inhibitor, on Ehrlich Carcinoma Model.
Carcinoma
Synergy between deacetylase inhibitors and IL-1beta in activation of the serum amyloid A2 gene promoter.
Carcinoma
The deacetylation-phosphorylation regulation of SIRT2-SMC1A axis as a mechanism of antimitotic catastrophe in early tumorigenesis.
Carcinoma
Trichostatin inhibits the growth of ACHN renal cell carcinoma cells via cell cycle arrest in association with p27, or apoptosis.
Carcinoma, Embryonal
Modulation of the embryotoxicity and cytotoxicity elicited by 7-hydroxy-2-acetylaminofluorene and acetaminophen via deacetylation.
Carcinoma, Hepatocellular
An Alternatively Spliced Sirtuin 2 Isoform 5 Inhibits Hepatitis B Virus Replication from cccDNA by Repressing Epigenetic Modifications Made by Histone Lysine Methyltransferases.
Carcinoma, Hepatocellular
Arylacetamide deacetylase attenuates fatty acid-induced triacylglycerol accumulation in rat hepatoma cells.
Carcinoma, Hepatocellular
CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma.
Carcinoma, Hepatocellular
Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report.
Carcinoma, Hepatocellular
Concurrent acetylation of FoxO1/3a and p53 due to sirtuins inhibition elicit Bim/PUMA mediated mitochondrial dysfunction and apoptosis in berberine-treated HepG2 cells.
Carcinoma, Hepatocellular
Identification of a cellularly active SIRT6 allosteric activator.
Carcinoma, Hepatocellular
Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis.
Carcinoma, Hepatocellular
Negative regulation of Sirtuin 1 by AMP-activated protein kinase promotes metformin-induced senescence in hepatocellular carcinoma xenografts.
Carcinoma, Hepatocellular
Reply to: "Histone deacetylase inhibitor for the treatment of hepatocellular carcinoma: Chemoimmunotherapeutic perspective and prospects".
Carcinoma, Hepatocellular
SIRT1 sensitizes hepatocellular carcinoma cells expressing hepatitis B virus X protein to oxidative stress-induced apoptosis.
Carcinoma, Non-Small-Cell Lung
Downregulation of SIRT6 is associated with poor prognosis in patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway.
Carcinoma, Non-Small-Cell Lung
SIRT6 drives epithelial-to-mesenchymal transition and metastasis in non-small cell lung cancer via snail-dependent transrepression of KLF4.
Carcinoma, Non-Small-Cell Lung
Vorinostat and metformin sensitize EGFR-TKI resistant NSCLC cells via BIM-dependent apoptosis induction.
Carcinoma, Ovarian Epithelial
Growth inhibition of pancreatic cancer cells by Histone Deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
Carcinoma, Renal Cell
SIRT1 knockdown up-regulates p53 and p21/Cip1 expression in renal adenocarcinoma cells but not in normal renal-derived cells in a deacetylase-independent manner.
Carcinoma, Renal Cell
Trichostatin inhibits the growth of ACHN renal cell carcinoma cells via cell cycle arrest in association with p27, or apoptosis.
Cardiomegaly
Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure.
Cardiomegaly
DPP (Dipeptidyl Peptidase)-4 Inhibitor Attenuates Ang II (Angiotensin II)-Induced Cardiac Hypertrophy via GLP (Glucagon-Like Peptide)-1-Dependent Suppression of Nox (Nicotinamide Adenine Dinucleotide Phosphate Oxidase) 4-HDAC (Histone Deacetylase) 4 Pathway.
Cardiomegaly
Friedreich's Ataxia reveals a mechanism for coordinate regulation of oxidative metabolism via feedback inhibition of the SIRT3 deacetylase.
Cardiomegaly
HDAC5 catalytic activity suppresses cardiomyocyte oxidative stress and NRF2 target gene expression.
Cardiomegaly
Nuclear import of histone deacetylase 5 by requisite nuclear localization signal phosphorylation.
Cardiomegaly
Panhistone deacetylase inhibitors inhibit proinflammatory signaling pathways to ameliorate interleukin-18-induced cardiac hypertrophy.
Cardiomegaly
Pressure overload-induced cardiac hypertrophy response requires janus kinase 2-histone deacetylase 2 signaling.
Cardiomegaly
Regulation of Acetylation of Histone Deacetylase 2 by p300/CBP-Associated Factor/Histone Deacetylase 5 in the Development of Cardiac Hypertrophy.
Cardiomegaly
Resveratrol Improves Cardiomyopathy in Dystrophin-deficient Mice through SIRT1 Protein-mediated Modulation of p300 Protein.
Cardiomegaly
SIRT2 Acts as a Cardioprotective Deacetylase in Pathological Cardiac Hypertrophy.
Cardiomegaly
Sirtuin 6 protects cardiomyocytes from hypertrophy in vitro via inhibition of NF-?B-dependent transcriptional activity.
Cardiomegaly
The Deacetylase SIRT1 Promotes Membrane Localization and Activation of Akt and PDK1 During Tumorigenesis and Cardiac Hypertrophy.
Cardiomegaly
Trichostatin A induces a unique set of microRNAs including miR-129-5p that blocks cyclin-dependent kinase 6 expression and proliferation in H9c2 cardiac myocytes.
Cardiomegaly
[The mechanism underlying histone deacetylases regulating cardiac hypertrophy].
Cardiomyopathies
TLR9 Binding to Beclin 1 and Mitochondrial SIRT3 by a Sodium-Glucose Co-Transporter 2 Inhibitor Protects the Heart from Doxorubicin Toxicity.
Cardiotoxicity
Dosing depending on SIRT3 activity attenuates doxorubicin-induced cardiotoxicity via elevated tolerance against mitochondrial dysfunction and oxidative stress.
Cardiotoxicity
Resveratrol protects against doxorubicin-induced cardiotoxicity in aged hearts through the SIRT1-USP7 axis.
Cardiotoxicity
Sirt3 promotes sensitivity to sunitinib-induced cardiotoxicity via inhibition of GTSP1/JNK/autophagy pathway in vivo and in vitro.
Cardiovascular Diseases
Ablation of SIRT3 causes coronary microvascular dysfunction and impairs cardiac recovery post myocardial ischemia.
Cardiovascular Diseases
Assessing the performance of three resveratrol in binding with SIRT1 by molecular dynamics simulation and MM/GBSA methods: the weakest binding of resveratrol 3 to SIRT1 triggers a possibility of dissociation from its binding site.
Cardiovascular Diseases
Effect of oral appliance on circulating leukocyte telomere length and SIRT1 in obstructive sleep apnea.
Cardiovascular Diseases
Mitochondrial Deacetylase Sirt3 Reduces Vascular Dysfunction and Hypertension While Sirt3 Depletion in Essential Hypertension Is Linked to Vascular Inflammation and Oxidative Stress.
Cardiovascular Diseases
Resveratrol-induced Sirt1 phosphorylation by LKB1 mediates mitochondrial metabolism.
Cardiovascular Diseases
Silent information regulator 2 homolog 1 counters cerebral hypoperfusion injury by deacetylating endothelial nitric oxide synthase.
Cardiovascular Diseases
SIRT3 is a novel prognostic biomarker for esophageal squamous cell carcinoma.
Cardiovascular Diseases
The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease.
Cholangitis
Sirtuin 1 activation alleviates primary biliary cholangitis via the blocking of the NF-?B signaling pathway.
Colitis
An inducible circular RNA circKcnt2 inhibits ILC3 activation to facilitate colitis resolution.
Colonic Neoplasms
Deacetylase Plus Bromodomain Inhibition Downregulates ERCC2 and Suppresses the Growth of Metastatic Colon Cancer Cells.
Colonic Neoplasms
Overexpression of Sirt6 is a novel biomarker of malignant human colon carcinoma.
Colonic Neoplasms
Structural Insight into the Interactions between Structurally Similar Inhibitors and SIRT6.
Colonic Neoplasms
The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth.
Colonic Neoplasms
X-ray crystal structures, density functional theory and docking on deacetylase enzyme for antiproliferative activity of hispolon derivatives on HCT116 colon cancer.
Colorectal Neoplasms
Discovery of Thieno[2,3-d]pyrimidine-Based Hydroxamic Acid Derivatives as Bromodomain-Containing Protein 4/Histone Deacetylase Dual Inhibitors Induce Autophagic Cell Death in Colorectal Carcinoma Cells.
Colorectal Neoplasms
Downregulation of SIRT7 by 5-fluorouracil induces radiosensitivity in human colorectal cancer.
Colorectal Neoplasms
Hypothesis: Retinoblastoma protein inactivation mediates effects of histone deacetylase inhibitor-induced Wnt hyperactivation in colorectal cancer cells.
Colorectal Neoplasms
SIRT1 suppresses colorectal cancer metastasis by transcriptional repression of miR-15b-5p.
Colorectal Neoplasms
Transcription factor PROX1 suppresses Notch pathway activation via the nucleosome remodeling and deacetylase complex in colorectal cancer stem-like cells.
Coronary Artery Disease
The Atherosclerosis Risk Variant rs2107595 Mediates Allele-Specific Transcriptional Regulation of HDAC9 via E2F3 and Rb1.
COVID-19
The unbalanced p53/SIRT1 axis may impact lymphocyte homeostasis in COVID-19 patients.
Cryptococcosis
Lanosterol 14?-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections.
Cysts
Inhibition of histone deacetylases targets the transcription regulator Id2 to attenuate cystic epithelial cell proliferation.
De Lange Syndrome
Modeling Cornelia de Lange Syndrome in vitro and in vivo reveals a role for cohesin complex in neuronal survival and differentiation.
De Lange Syndrome
NIPBL Controls RNA Biogenesis to Prevent Activation of the Stress Kinase PKR.
Demyelinating Diseases
SIRT1 Activating compounds reduce oxidative stress mediated neuronal loss in viral induced CNS demyelinating disease.
Dermatomyositis
Association Between Autoantibody Phenotype and Cutaneous Adverse Reactions to Hydroxychloroquine in Dermatomyositis.
Diabetes Complications
SIRT1 suppresses cardiomyocyte apoptosis in diabetic cardiomyopathy: An insight into endoplasmic reticulum stress response mechanism.
Diabetes Mellitus
N1-Methylnicotinamide Improves Hepatic Insulin Sensitivity via Activation of SIRT1 and Inhibition of FOXO1 Acetylation.
Diabetes Mellitus
SIRT1 alleviates diabetic neuropathic pain by regulating synaptic plasticity of spinal dorsal horn neurons.
Diabetes Mellitus, Type 1
Dietary advanced glycated end-products and medicines influence the expression of SIRT1 and DDOST in peripheral mononuclear cells from long-term type 1 diabetes patients.
Diabetes Mellitus, Type 2
A Label-free Sirtuin 1 Assay based on Droplet-Electrospray Ionization Mass Spectrometry.
Diabetes Mellitus, Type 2
N1-Methylnicotinamide Improves Hepatic Insulin Sensitivity via Activation of SIRT1 and Inhibition of FOXO1 Acetylation.
Diabetes Mellitus, Type 2
Protective effects of sirtuins in cardiovascular diseases: from bench to bedside.
Diabetes Mellitus, Type 2
Resveratrol-induced Sirt1 phosphorylation by LKB1 mediates mitochondrial metabolism.
Diabetes Mellitus, Type 2
SIRT1 alleviates diabetic neuropathic pain by regulating synaptic plasticity of spinal dorsal horn neurons.
Diabetic Nephropathies
Sirt1 inhibits renal tubular cell epithelial-mesenchymal transition through YY1 deacetylation in diabetic nephropathy.
Diabetic Nephropathies
Sirt3 overexpression alleviates hyperglycemia-induced vascular inflammation through regulating redox balance, cell survival, and AMPK-mediated mitochondrial homeostasis.
Diffuse Intrinsic Pontine Glioma
The distribution, clearance, and brainstem toxicity of panobinostat administered by convection-enhanced delivery.
Encephalitis
The NAD-dependent deacetylase sirtuin 2 is a suppressor of microglial activation and brain inflammation.
Encephalomyelitis
A T cell-specific deletion of HDAC1 protects against experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
A T cell-specific deletion of HDAC1 protects against experimental autoimmune encephalomyelitis.
Endometrial Neoplasms
MicroRNA as Epigenetic Modifiers in Endometrial Cancer: A Systematic Review.
Endometrial Neoplasms
Sirtuin 2 promotes cell stemness and MEK/ERK signaling pathway while reduces chemosensitivity in endometrial cancer.
Enzootic Bovine Leukosis
Deacetylase inhibitors and the viral transactivator TaxBLV synergistically activate bovine leukemia virus gene expression via a cAMP-responsive element- and cAMP-responsive element-binding protein-dependent mechanism.
Epilepsy
Altered mitochondrial acetylation profiles in a kainic acid model of temporal lobe epilepsy.
Esophageal Neoplasms
Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells.
Essential Hypertension
Letter by Zhou et al Regarding Article, "Mitochondrial Deacetylase Sirt3 Reduces Vascular Dysfunction and Hypertension While Sirt3 Depletion in Essential Hypertension Is Linked to Vascular Inflammation and Oxidative Stress".
Essential Hypertension
Mitochondrial Deacetylase Sirt3 Reduces Vascular Dysfunction and Hypertension While Sirt3 Depletion in Essential Hypertension Is Linked to Vascular Inflammation and Oxidative Stress.
Essential Hypertension
Response by Dikalova and Dikalov to Letter Regarding Article, "Mitochondrial Deacetylase Sirt3 Reduces Vascular Dysfunction and Hypertension While Sirt3 Depletion in Essential Hypertension Is Linked to Vascular Inflammation and Oxidative Stress".
Fatty Liver
A polyphenol extract modifies quantity but not quality of liver fatty acid content in high-fat-high-sucrose diet-fed rats: possible implication of the sirtuin pathway.
Fatty Liver
Activation of the aryl hydrocarbon receptor sensitizes mice to non-alcoholic steatohepatitis by deactivating the mitochondrial sirtuin deacetylase Sirt3.
Fatty Liver
Dietary soya protein concentrate enriched with isoflavones reduced fatty liver, increased hepatic fatty acid oxidation and decreased the hepatic mRNA level of VLDL receptor in obese Zucker rats.
Fatty Liver
Effect of Caloric Restriction and AMPK Activation on Hepatic Nuclear Receptor, Biotransformation Enzyme, and Transporter Expression in Lean and Obese Mice.
Fatty Liver
Folic acid attenuates high-fat diet-induced steatohepatitis via deacetylase SIRT1-dependent restoration of PPAR?.
Fatty Liver
Protective effects of sirtuins in cardiovascular diseases: from bench to bedside.
Fatty Liver
SIRT1 upregulation protects against liver injury induced by a HFD through inhibiting CD36 and the NF??B pathway in mouse kupffer cells.
Fatty Liver
SIRT7 represses Myc activity to suppress ER stress and prevent fatty liver disease.
Friedreich Ataxia
Friedreich's Ataxia reveals a mechanism for coordinate regulation of oxidative metabolism via feedback inhibition of the SIRT3 deacetylase.
Genetic Diseases, Inborn
Analysis of post-transcriptional regulation using the FunREG method.
Glioblastoma
Aberrant Transcriptional Regulation of Super-enhancers by RET Finger Protein-histone Deacetylase 1 Complex in Glioblastoma: Chemoresistance to Temozolomide.
Glioblastoma
Correction to: The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.
Glioblastoma
HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma.
Glioblastoma
Metabolic Effects of Known and Novel HDAC and SIRT Inhibitors in Glioblastomas Independently or Combined with Temozolomide.
Glioblastoma
SIRT2-mediated inactivation of p73 is required for glioblastoma tumorigenicity.
Glioblastoma
The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.
Glioma
Convection enhanced delivery of panobinostat (LBH589)-loaded pluronic nano-micelles prolongs survival in the F98 rat glioma model.
Glioma
EX527, a Sirt-1 inhibitor, induces apoptosis in glioma via activating the p53 signaling pathway.
Glioma
Interplay between TRAP1 and sirtuin-3 modulates mitochondrial respiration and oxidative stress to maintain stemness of glioma stem cells.
Glioma
SIRT2 downregulation confers resistance to microtubule inhibitors by prolonging chronic mitotic arrest.
Glioma
The distribution, clearance, and brainstem toxicity of panobinostat administered by convection-enhanced delivery.
Glioma
The histone deacetylase SIRT6 suppresses the expression of the RNA-binding protein PCBP2 in glioma.
Granulosa Cell Tumor
Transcription factor FOXL2 protects granulosa cells from stress and delays cell cycle: role of its regulation by the SIRT1 deacetylase.
Hearing Loss
SIRT3 deacetylates isocitrate dehydrogenase 2 (IDH2) and regulates mitochondrial redox status.
Hearing Loss
Sulforaphane attenuates cisplatin-induced hearing loss by inhibiting histone deacetylase expression.
Hearing Loss, Sensorineural
Nuclear Factor Erythroid 2-Related Factor 2-Histone Deacetylase 2 Pathway in the Pathogenesis of Refractory Sudden Sensorineural Hearing Loss and Glucocorticoid Resistance.
Heart Diseases
Anti-correlation between longevity gene SirT1 and Notch signaling in ascending aorta biopsies from patients with bicuspid aortic valve disease.
Heart Diseases
Histone deacetylase adaptation in single ventricle heart disease and a young animal model of right ventricular hypertrophy.
Heart Failure
Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure.
Heart Failure
Histone deacetylase inhibitor SAHA treatment prevents the development of heart failure after myocardial infarction via an induction of heat-shock proteins in rats.
Heart Failure
Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity.
Heart Failure
Resveratrol Ameliorates Muscular Pathology in the Dystrophic mdx Mouse, a Model for Duchenne Muscular Dystrophy.
Heart Failure
TLR9 Binding to Beclin 1 and Mitochondrial SIRT3 by a Sodium-Glucose Co-Transporter 2 Inhibitor Protects the Heart from Doxorubicin Toxicity.
Hematologic Neoplasms
Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models.
Hematologic Neoplasms
Growth inhibition of pancreatic cancer cells by Histone Deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
Hematologic Neoplasms
HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells.
Hematologic Neoplasms
SIRT1 regulates the phosphorylation and degradation of P27 by deacetylating CDK2 to promote T-cell acute lymphoblastic leukemia progression.
Hematologic Neoplasms
The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
Hematologic Neoplasms
Vorinostat and quinacrine have synergistic effects in T-cell acute lymphoblastic leukemia through reactive oxygen species increase and mitophagy inhibition.
Hemochromatosis
Hepcidin is regulated by promoter-associated histone acetylation and HDAC3.
Hepatitis
The SIRT1 inhibitor, nicotinamide, inhibits hepatitis B virus replication in vitro and in vivo.
Hepatitis B
Hepatitis B virus X (HBX) protein upregulates ?-catenin in a human hepatic cell line by sequestering SIRT1 deacetylase.
Hepatitis B
SIRT1 sensitizes hepatocellular carcinoma cells expressing hepatitis B virus X protein to oxidative stress-induced apoptosis.
HIV Infections
Arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of Rifapentine: a population pharmacokinetics analysis.
Hodgkin Disease
A Phase 2 Study of Vorinostat for Treatment of Relapsed or Refractory Hodgkin Lymphoma: Southwest Oncology Group Study S0517.
Hodgkin Disease
Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.
Huntington Disease
Design and Evaluation of 3-(Benzylthio)benzamide Derivatives as Potent and Selective SIRT2 Inhibitors.
Huntington Disease
Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors.
Huntington Disease
Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets.
Huntington Disease
The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models.
Hyperglycemia
Resveratrol ameliorates hyperglycemia-induced renal tubular oxidative stress damage via modulating the SIRT1/FOXO3a pathway.
Hyperlipidemias
Resveratrol promotes white adipocytes browning and improves metabolic disorders in Sirt1-dependent manner in mice.
Hypersensitivity
SIRT1 deacetylase in POMC neurons is required for homeostatic defenses against diet-induced obesity.
Hypertension
Activation of SIRT1 Attenuates Klotho Deficiency-Induced Arterial Stiffness and Hypertension by Enhancing AMP-Activated Protein Kinase Activity.
Hypertension
Letter by Zhou et al Regarding Article, "Mitochondrial Deacetylase Sirt3 Reduces Vascular Dysfunction and Hypertension While Sirt3 Depletion in Essential Hypertension Is Linked to Vascular Inflammation and Oxidative Stress".
Hypertension
Lysine deacetylase inhibition attenuates hypertension and is accompanied by acetylation of mineralocorticoid receptor instead of histone acetylation in spontaneously hypertensive rats.
Hypertension
Mitochondrial Deacetylase Sirt3 Reduces Vascular Dysfunction and Hypertension While Sirt3 Depletion in Essential Hypertension Is Linked to Vascular Inflammation and Oxidative Stress.
Hypertension
Mitochondrial Isolevuglandins Contribute to Vascular Oxidative Stress and Mitochondria-Targeted Scavenger of Isolevuglandins Reduces Mitochondrial Dysfunction and Hypertension.
Hypertension
Response by Dikalova and Dikalov to Letter Regarding Article, "Mitochondrial Deacetylase Sirt3 Reduces Vascular Dysfunction and Hypertension While Sirt3 Depletion in Essential Hypertension Is Linked to Vascular Inflammation and Oxidative Stress".
Hypertrophy, Left Ventricular
Sirt3 Deficiency Does not Augment Hypoxia-Induced Pulmonary Hypertension.
Infarction, Middle Cerebral Artery
Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain.
Infections
A new class of UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC) inhibitors for the treatment of Gram-negative infections: PCT application WO 2008027466.
Infections
Comparative effects of histone deacetylases inhibitors and resveratrol on Trypanosoma cruzi replication, differentiation, infectivity and gene expression.
Infections
Epigenetic factor siRNA screen during primary KSHV infection identifies novel host restriction factors for the lytic cycle of KSHV.
Infections
HDAC6 Restricts Influenza A Virus by Deacetylation of the RNA Polymerase PA Subunit.
Infections
Influenza A virus dysregulates host histone deacetylase 1 that inhibits viral infection in lung epithelial cells.
Infections
Lanosterol 14?-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections.
Infections
Proteome-wide lysine acetylation in cortical astrocytes and alterations that occur during infection with brain parasite Toxoplasma gondii.
Infections
Rabies Virus Infection Induces Microtubule Depolymerization to Facilitate Viral RNA Synthesis by Upregulating HDAC6.
Infections
Resveratrol therapeutics combines both antimicrobial and immunomodulatory properties against respiratory infection by nontypeable Haemophilus influenzae.
Infections
Role of acetylases and deacetylase inhibitors in IRF-1-mediated HIV-1 long terminal repeat transcription.
Infections
Sirtuin 3 is essential for host defense against Mycobacterium abscessus infection through regulation of mitochondrial homeostasis.
Infections
Sirtuin1 Targeting Reverses Innate and Adaptive Immune Tolerance in Septic Mice.
Infections
Structural basis of the promiscuous inhibitor susceptibility of Escherichia coli LpxC.
Infections
Synthesis, biological evaluation and molecular docking studies of benzyloxyacetohydroxamic acids as LpxC inhibitors.
Infections
Synthesis, Structure, and Antibiotic Activity of Aryl-Substituted LpxC Inhibitors.
Infections
The antiviral sirtuin 3 bridges protein acetylation to mitochondrial integrity and metabolism during human cytomegalovirus infection.
Infections
Treatment of human challenge and MDR strains of Neisseria gonorrhoeae with LpxC inhibitors.
Infertility, Male
Phloem transport of D,L-glufosinate and acetyl-L-glufosinate in glufosinate-resistant and -susceptible brassica napus
Insulin Resistance
CLOCK/BMAL1 regulates circadian change of mouse hepatic insulin sensitivity via SIRT1.
Insulin Resistance
Exercise Training Improves Whole Body Insulin Resistance via Adiponectin Receptor 1.
Insulin Resistance
Involvement of nitric oxide synthase/nitric oxide pathway in the regulation of SIRT1-AMPK crosstalk in podocytes: Impact on glucose uptake.
Insulin Resistance
Metformin overcomes high glucose-induced insulin resistance of podocytes by pleiotropic effects on SIRT1 and AMPK.
Insulin Resistance
Modulation of the Inflammatory Status of Macrophages and Their Paracrine Effect on the Sensitivity of Adipocytes to Insulin with Sirtuin and PPAR? Receptor Activators.
Insulin Resistance
N1-Methylnicotinamide Improves Hepatic Insulin Sensitivity via Activation of SIRT1 and Inhibition of FOXO1 Acetylation.
Insulin Resistance
Proatherogenic abnormalities of lipid metabolism in SirT1 transgenic mice are mediated through Creb deacetylation.
Insulin Resistance
Resveratrol attenuates excessive ethanol exposure induced insulin resistance in rats via improving NAD(+) /NADH ratio.
Insulin Resistance
SIRT1-AMPK crosstalk is involved in high glucose-dependent impairment of insulin responsiveness in primary rat podocytes.
Insulin Resistance
Sirt6 deletion in hepatocytes increases insulin sensitivity of female mice by enhancing ER? expression.
Insulin Resistance
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
Insulin Resistance
Suppression of SIRT1 in Diabetic Conditions Induces Osteogenic Differentiation of Human Vascular Smooth Muscle Cells via RUNX2 Signalling.
Insulin Resistance
Temporal overexpression of SIRT1 in skeletal muscle of adult mice does not improve insulin sensitivity or markers of mitochondrial biogenesis.
Insulin Resistance
The NAD+-dependent deacetylase SIRT2 attenuates oxidative stress and mitochondrial dysfunction and improves insulin sensitivity in hepatocytes.
Intellectual Disability
HDAC4 governs a transcriptional program essential for synaptic plasticity and memory.
Intellectual Disability
Modeling Cornelia de Lange Syndrome in vitro and in vivo reveals a role for cohesin complex in neuronal survival and differentiation.
Intellectual Disability
Regulation of neuronal connectivity in the mammalian brain by chromatin remodeling.
Invasive Fungal Infections
RcLS2F - A Novel Fungal Class 1 KDAC Co-repressor Complex in Aspergillus nidulans.
Iron Deficiencies
Hepcidin is regulated by promoter-associated histone acetylation and HDAC3.
Ischemic Stroke
Downregulation of NAD-Dependent Deacetylase SIRT2 Protects Mouse Brain Against Ischemic Stroke.
Kidney Diseases
In vivo RNA interference models of inducible and reversible Sirt1 knockdown in kidney cells.
Kidney Diseases
SIRT1 inhibits transforming growth factor beta-induced apoptosis in glomerular mesangial cells via Smad7 deacetylation.
Latent Infection
Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection.
Leiomyoma
Ovarian steroid hormones modulate the expression of progesterone receptors and histone acetylation patterns in uterine leiomyoma cells.
Leukemia
Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO.
Leukemia
Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
Leukemia
Corrections: Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine.
Leukemia
Differential Type I Interferon-dependent Transgene Silencing of Helper-dependent Adenoviral vs. Adeno-associated Viral Vectors In Vivo.
Leukemia
FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction.
Leukemia
Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.
Leukemia
Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Leukemia
Recruitment of SMRT/N-CoR-mSin3A-HDAC-repressing complexes is not a general mechanism for BTB/POZ transcriptional repressors: the case of HIC-1 and gammaFBP-B.
Leukemia
Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia.
Leukemia
Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine.
Leukemia
Role of SIRT1 in the growth and regulation of normal hematopoietic and leukemia stem cells.
Leukemia
Sirtuin 1 Activation Suppresses the Growth of T-lymphoblastic Leukemia Cells by Inhibiting NOTCH and NF-?B Pathways.
Leukemia
The DAC system and associations with acute leukemias and myelodysplastic syndromes.
Leukemia
The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
Leukemia, Erythroblastic, Acute
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.
Leukemia, Lymphocytic, Chronic, B-Cell
Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[microRNA targeted to chronic myeloid leukemia Bcr-Abl oncogene screen using deacetylase inhibitor].
Leukemia, Myeloid, Acute
A novel alkylating deacetylase inhibitor molecule EDO-S101 in combination with cytarabine synergistically enhances apoptosis of acute myeloid leukemia cells.
Leukemia, Myeloid, Acute
Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO.
Leukemia, Myeloid, Acute
Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.
Leukemia, Myeloid, Acute
Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study.
Leukemia, Myeloid, Acute
Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo.
Leukemia, Myeloid, Acute
Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
Leukemia, Promyelocytic, Acute
Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO.
Leukemia-Lymphoma, Adult T-Cell
LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway.
Liver Cirrhosis
SIRT1 antagonizes liver fibrosis by blocking hepatic stellate cell activation in mice.
Liver Cirrhosis
Withaferin A Exerts Preventive Effect on Liver Fibrosis through Oxidative Stress Inhibition in a Sirtuin 3-Dependent Manner.
Liver Cirrhosis, Biliary
Sirtuin 1 activation alleviates primary biliary cholangitis via the blocking of the NF-?B signaling pathway.
Liver Diseases
Molecular, Cellular, and Physiological Characterization of Sirtuin 7 (SIRT7).
Liver Diseases
Obesity-Linked Phosphorylation of SIRT1 by Casein Kinase 2 Inhibits Its Nuclear Localization and Promotes Fatty Liver.
Liver Diseases
Salvianolic acid A preconditioning confers protection against concanavalin A-induced liver injury through SIRT1-mediated repression of p66shc in mice.
Liver Diseases
Sirt1 is involved in energy metabolism: the role of chronic ethanol feeding and resveratrol.
Liver Diseases
SIRT1 upregulation protects against liver injury induced by a HFD through inhibiting CD36 and the NF??B pathway in mouse kupffer cells.
Liver Diseases
SIRT7 represses Myc activity to suppress ER stress and prevent fatty liver disease.
Liver Diseases, Alcoholic
Alcohol-induced defects in hepatic transcytosis may be explained by impaired dynein function.
Liver Diseases, Alcoholic
Hepatic microtubule acetylation and stability induced by chronic alcohol exposure impair nuclear translocation of STAT3 and STAT5B, but not Smad2/3.
Liver Neoplasms
Autophagy-related cell death by pan-histone deacetylase inhibition in liver cancer.
Liver Neoplasms
Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis.
Lung Injury
Restoration of SIRT3 gene expression by airway delivery resolves age-associated persistent lung fibrosis in mice.
Lung Neoplasms
A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity.
Lung Neoplasms
Downregulation of SIRT6 is associated with poor prognosis in patients with non-small cell lung cancer.
Lung Neoplasms
Early growth response-1 induces and enhances vascular endothelial growth factor-a expression in lung cancer cells.
Lung Neoplasms
Growth inhibition of pancreatic cancer cells by Histone Deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
Lung Neoplasms
Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway.
Lung Neoplasms
Rosiglitazone Prevents the Progression of Pre-invasive Lung Cancer in a Murine Model.
Lung Neoplasms
SIRT6 drives epithelial-to-mesenchymal transition and metastasis in non-small cell lung cancer via snail-dependent transrepression of KLF4.
Lung Neoplasms
Sirtuin 3 induces apoptosis and necroptosis by regulating mutant p53 expression in small?cell lung cancer.
Lung Neoplasms
Suppression of Sirt1 sensitizes lung cancer cells to WEE1 inhibitor MK-1775-induced DNA damage and apoptosis.
Lung Neoplasms
Targeting the invasive phenotype of cisplatin-resistant Non-Small Cell Lung Cancer cells by a novel histone deacetylase inhibitor.
Lung Neoplasms
Vorinostat and metformin sensitize EGFR-TKI resistant NSCLC cells via BIM-dependent apoptosis induction.
Lymphoma
Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: A highly active combination against human mantle cell lymphoma (MCL) cells.
Lymphoma
Evolving Strategies for the Treatment of T-Cell Lymphoma: A Systematic Review and Recent Patents.
Lymphoma
Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents.
Lymphoma
Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy.
Lymphoma
Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma.
Lymphoma
Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.
Lymphoma
Recruitment of SMRT/N-CoR-mSin3A-HDAC-repressing complexes is not a general mechanism for BTB/POZ transcriptional repressors: the case of HIC-1 and gammaFBP-B.
Lymphoma
Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts.
Lymphoma
Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma.
Lymphoma, B-Cell
Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway.
Lymphoma, B-Cell
Recruitment of SMRT/N-CoR-mSin3A-HDAC-repressing complexes is not a general mechanism for BTB/POZ transcriptional repressors: the case of HIC-1 and gammaFBP-B.
Lymphoma, B-Cell
SIRT3, a metabolic target linked to ataxia-telangiectasia mutated (ATM) gene deficiency in diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
SIRT3, a metabolic target linked to ataxia-telangiectasia mutated (ATM) gene deficiency in diffuse large B-cell lymphoma.
Lymphoma, Non-Hodgkin
Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study.
Lymphoma, T-Cell, Cutaneous
Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
Lymphoma, T-Cell, Cutaneous
Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo.
Lymphoma, T-Cell, Cutaneous
Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism.
Lymphoma, T-Cell, Cutaneous
Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.
Lymphoma, T-Cell, Peripheral
Inhibition of human UDP-glucuronosyltransferase enzyme by belinostat: Implications for drug-drug interactions.
Malaria
Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth.
Malocclusion
Epigenetic influence of KAT6B and HDAC4 in the development of skeletal malocclusion.
Mastocytoma
Functional analysis of conserved cysteines in heparan sulfate N-deacetylase-N-sulfotransferases.
Melanoma
Activation of the SIRT1 pathway and modulation of the cell cycle were involved in silymarin's protection against UV-induced A375-S2 cell apoptosis.
Melanoma
Association Between Autoantibody Phenotype and Cutaneous Adverse Reactions to Hydroxychloroquine in Dermatomyositis.
Melanoma
Deacetylase inhibition in malignant melanomas: impact on cell cycle regulation and survival.
Melanoma
Down-regulation of deacetylase HDAC6 inhibits the melanoma cell line A375.S2 growth through ROS-dependent mitochondrial pathway.
Melanoma
Indocyanine Green-Nexturastat A-PLGA Nanoparticles Combine Photothermal and Epigenetic Therapy for Melanoma.
Melanoma
Nucleus accumbens-associated 1 contributes to cortactin deacetylation and augments the migration of melanoma cells.
Melanoma
Pro-Proliferative Function of Mitochondrial Sirtuin Deacetylase SIRT3 in Human Melanoma.
Melanoma
SIRT1 deacetylase is overexpressed in human melanoma and its small molecule inhibition imparts anti-proliferative response via p53 activation.
Melanoma
The nucleosome remodeling and deacetylase complex has prognostic significance and associates with immune microenvironment in skin cutaneous melanoma.
Metabolic Diseases
A pathway involving farnesoid X receptor and small heterodimer partner positively regulates hepatic sirtuin 1 levels via microRNA-34a inhibition.
Metabolic Diseases
Anti-obesity Activity of Ethanol Extract from Bitter Melon in Mice Fed High-Fat Diet.
Metabolic Diseases
Continuous multiparametric monitoring of cell metabolism in response to transient overexpression of the sirtuin deacetylase SIRT3.
Metabolic Diseases
Indole-3-carbinol directly targets SIRT1 to inhibit adipocyte differentiation.
Metabolic Diseases
PRMT1 and PRMT4 Regulate Oxidative Stress-Induced Retinal Pigment Epithelial Cell Damage in SIRT1-Dependent and SIRT1-Independent Manners.
Metabolic Diseases
SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase.
Metabolic Diseases
Sirtuin 1 alleviates endoplasmic reticulum stress-mediated apoptosis of intestinal epithelial cells in ulcerative colitis.
Metabolic Syndrome
Mitochondrial SIRT3: a new potential therapeutic target for metabolic syndrome.
Metabolic Syndrome
The SIRT1 deacetylase protects mice against the symptoms of metabolic syndrome.
Methemoglobinemia
Metabolic activation by human arylacetamide deacetylase, CYP2E1, and CYP1A2 causes phenacetin-induced methemoglobinemia.
Multiple Myeloma
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.
Multiple Myeloma
Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma.
Multiple Myeloma
Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma.
Multiple Myeloma
HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells.
Multiple Myeloma
Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma.
Multiple Myeloma
Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001.
Multiple Myeloma
Panbinostat decreases cFLIP and enhances killing of cancer cells by immunotoxin LMB-100 by stimulating the extrinsic apoptotic pathway.
Multiple Myeloma
Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma.
Multiple Myeloma
Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy.
Multiple Myeloma
The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.
Multiple Sclerosis
Targeting foam cell formation in inflammatory brain diseases by the histone modifier MS-275.
Muscular Atrophy
HDAC1 activates FoxO and is both sufficient and required for skeletal muscle atrophy.
Muscular Atrophy
Muscle-specific sirtuin1 gain-of-function ameliorates skeletal muscle atrophy in a pre-clinical mouse model of cerebral ischemic stroke.
Muscular Atrophy
SIRT1 by blocking the activities of FoxO1 and 3 inhibits muscle atrophy and promotes muscle growth.
Muscular Dystrophies
Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors.
Muscular Dystrophy, Duchenne
Low doses of arginine butyrate derivatives improve dystrophic phenotype and restore membrane integrity in DMD models.
Muscular Dystrophy, Duchenne
Resveratrol Decreases Oxidative Stress by Restoring Mitophagy and Improves the Pathophysiology of Dystrophin-Deficient mdx Mice.
Muscular Dystrophy, Oculopharyngeal
Cross-talk between canonical Wnt signaling and the sirtuin-FoxO longevity pathway to protect against muscular pathology induced by mutant PABPN1 expression in C. elegans.
Myelodysplastic Syndromes
Deacetylase inhibitors for the treatment of myelodysplastic syndromes.
Myelodysplastic Syndromes
Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome.
Myocardial Infarction
Protective effects of sirtuins in cardiovascular diseases: from bench to bedside.
Myocardial Infarction
The NAD-dependent deacetylase SIRT2 is required for programmed necrosis.
Myositis
Decreased SIRT1 deacetylase activity in sporadic inclusion-body myositis muscle fibers.
nadh:ubiquinone reductase (h+-translocating) deficiency
Oxidative stress contributes differentially to the pathophysiology of Charcot-Marie-Tooth disease type 2K.
Neoplasm Metastasis
A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage.
Neoplasm Metastasis
Aberrant HDAC3 expression correlates with brain metastasis in breast cancer patients.
Neoplasm Metastasis
Alterations of BRMS1-ARID4A Interaction Modify Gene Expression but Still Suppress Metastasis in Human Breast Cancer Cells.
Neoplasm Metastasis
Breaking down the Contradictory Roles of Histone Deacetylase SIRT1 in Human Breast Cancer.
Neoplasm Metastasis
BRMS1L suppresses breast cancer metastasis by inducing epigenetic silence of FZD10.
Neoplasm Metastasis
Expression patterns of class I histone deacetylases in osteosarcoma: a novel prognostic marker with potential therapeutic implications.
Neoplasm Metastasis
Hypoxia-induced NAD+ interventions promote tumor survival and metastasis by regulating mitochondrial dynamics.
Neoplasm Metastasis
Intercellular transfer of proteins as identified by stable isotope labeling of amino acids in cell culture.
Neoplasm Metastasis
Involvement of a chromatin modifier in response to mono-(2-ethylhexyl) phthalate (MEHP)-induced Sertoli cell injury: probably an indirect action via the regulation of NF?B/FasL circuitry.
Neoplasm Metastasis
Metastasis-associated protein 1-mediated antitumor and anticancer activity of dietary stilbenes for prostate cancer chemoprevention and therapy.
Neoplasm Metastasis
MTA1 and MTA3 Regulate HIF1a Expression in Hypoxia-Treated Human Trophoblast Cell Line HTR8/Svneo.
Neoplasm Metastasis
Overexpression of Sirt6 is a novel biomarker of malignant human colon carcinoma.
Neoplasm Metastasis
SIRT1 deacetylates KLF4 to activate Claudin-5 transcription in ovarian cancer cells.
Neoplasm Metastasis
SIRT1 regulates N6 -methyladenosine RNA modification in hepatocarcinogenesis by inducing RANBP2-dependent FTO SUMOylation.
Neoplasm Metastasis
SIRT1 suppresses the migration and invasion of gastric cancer by regulating ARHGAP5 expression.
Neoplasm Metastasis
SIRT6 drives epithelial-to-mesenchymal transition and metastasis in non-small cell lung cancer via snail-dependent transrepression of KLF4.
Neoplasm Metastasis
SIRT7 antagonizes TGF-? signaling and inhibits breast cancer metastasis.
Neoplasm Metastasis
SUMOylation and SUMO-interacting motif (SIM) of metastasis tumor antigen 1 (MTA1) synergistically regulate its transcriptional repressor function.
Neoplasms
A biotin switch-based proteomics approach identifies 14-3-3? as a target of Sirt1 in the metabolic regulation of caspase-2.
Neoplasms
A Label-free Sirtuin 1 Assay based on Droplet-Electrospray Ionization Mass Spectrometry.
Neoplasms
A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors.
Neoplasms
A pathway involving farnesoid X receptor and small heterodimer partner positively regulates hepatic sirtuin 1 levels via microRNA-34a inhibition.
Neoplasms
A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors.
Neoplasms
A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy.
Neoplasms
An update on drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors.
Neoplasms
Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells.
Neoplasms
Apoptosis Induction byHistone Deacetylase Inhibitors in Cancer Cells: Role of Ku70.
Neoplasms
Aromatase Acetylation Patterns and Altered Activity in Response to Sirtuin Inhibition.
Neoplasms
Arsenic trioxide exerts antimyeloma effects by inhibiting activity in the cytoplasmic substrates of histone deacetylase 6.
Neoplasms
Association of SIRT1 and tumor suppressor gene TAp63 expression in head and neck squamous cell carcinoma.
Neoplasms
Breaking down the Contradictory Roles of Histone Deacetylase SIRT1 in Human Breast Cancer.
Neoplasms
BRMS1L suppresses breast cancer metastasis by inducing epigenetic silence of FZD10.
Neoplasms
CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status.
Neoplasms
Class I histone deacetylases sequentially interact with MyoD and pRb during skeletal myogenesis.
Neoplasms
Combination of Pan-HDAC Inhibitor and COX-2 Inhibitor Produces Synergistic Anticancer Effects in Human Salivary Adenoid Cystic Cancer Cells.
Neoplasms
Combination of sirtuin 3 and hyperoxia diminishes tumorigenic properties of MDA-MB-231 cells.
Neoplasms
Conjugate of Pt (IV)-Histone Deacetylase Inhibitor as Prodrug for Cancer Chemotherapy.
Neoplasms
Context-dependent activation of SIRT3 is necessary for anchorage-independent survival and metastasis of ovarian cancer cells.
Neoplasms
Continuous multiparametric monitoring of cell metabolism in response to transient overexpression of the sirtuin deacetylase SIRT3.
Neoplasms
Correction: Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor.
Neoplasms
Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5.
Neoplasms
Deacetylase activity of human tumor cells producing immunosuppressive aminosugars: its possible role in resistance to cell-mediated cytotoxicity.
Neoplasms
Deacetylase inhibitors dissociate the histone-targeting ING2 subunit from the Sin3 complex.
Neoplasms
Deregulation of polyamine biosynthesis alters intrinsic histone acetyltransferase and deacetylase activities in murine skin and tumors.
Neoplasms
Differential Expression of Circadian Genes in Leukemia and a Possible Role for Sirt1 in Restoring the Circadian Clock in Chronic Myeloid Leukemia.
Neoplasms
Differential SIRT1 Expression in Hepatocellular Carcinomas and Cholangiocarcinoma of the Liver.
Neoplasms
Discovery of New SIRT2 Inhibitors by Utilizing a Consensus Docking/Scoring Strategy and Structure-Activity Relationship Analysis.
Neoplasms
E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells.
Neoplasms
Early growth response-1 induces and enhances vascular endothelial growth factor-a expression in lung cancer cells.
Neoplasms
Endothelial cells from umbilical cord of women affected by gestational diabetes: A suitable in vitro model to study mechanisms of early vascular senescence in diabetes.
Neoplasms
Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation.
Neoplasms
Epigenetic mechanisms in anti-cancer actions of bioactive food components - the implications in cancer prevention.
Neoplasms
Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor.
Neoplasms
Function of the SIRT3 mitochondrial deacetylase in cellular physiology, cancer, and neurodegenerative disease.
Neoplasms
Growth inhibition of pancreatic cancer cells by Histone Deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
Neoplasms
Guizhi-Shaoyao-Zhimu decoction attenuates rheumatoid arthritis partially by reversing inflammation-immune system imbalance.
Neoplasms
HDAC4 protein regulates HIF1? protein lysine acetylation and cancer cell response to hypoxia.
Neoplasms
HDAC6 activity is not required for basal autophagic flux in metastatic prostate cancer cells.
Neoplasms
Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study.
Neoplasms
Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells.
Neoplasms
Histone deacetylase enzymes as potential drug targets in cancer and parasitic diseases.
Neoplasms
Honokiol Bis-Dichloroacetate Is a Selective Allosteric Inhibitor of the Mitochondrial Chaperone TRAP1.
Neoplasms
Hypoxia-induced NAD+ interventions promote tumor survival and metastasis by regulating mitochondrial dynamics.
Neoplasms
Identification of acetylation-dependent regulatory mechanisms that govern the oncogenic functions of Skp2.
Neoplasms
Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways.
Neoplasms
Identification of Sirtuin 3, a mitochondrial protein deacetylase, as a new contributor to tamoxifen resistance in breast cancer cells.
Neoplasms
In Vitro Effect of the Histone Deacetylase Inhibitor Valproic Acid on Viability and Apoptosis of the PLC/PRF5 Human Hepatocellular Carcinoma Cell Line
Neoplasms
In vivo monitoring of the anti-angiogenic therapeutic effect of the pan-deacetylase inhibitor panobinostat by small animal PET in a mouse model of gastrointestinal cancers.
Neoplasms
Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
Neoplasms
Inhibition of HDAC6 activity through interaction with RanBPM and its associated CTLH complex.
Neoplasms
Inhibition of SIRT1 deacetylase and p53 activation uncouples the anti-inflammatory and chemopreventive actions of NSAIDs.
Neoplasms
Insight into the Mechanism of Intramolecular Inhibition of the Catalytic Activity of Sirtuin 2 (SIRT2).
Neoplasms
Liver-Targeting Class I Selective Histone Deacetylase Inhibitors Potently Suppress Hepatocellular Tumor Growth as Standalone Agents.
Neoplasms
Megakaryocyte lineage development is controlled by modulation of protein acetylation.
Neoplasms
Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A-histone deacetylase complex.
Neoplasms
Mesenchymal stem cells overexpressing Sirt1 inhibit prostate cancer growth by recruiting natural killer cells and macrophages.
Neoplasms
Methylation-directed acetylation of histone H3 regulates developmental sensitivity to histone deacetylase inhibition.
Neoplasms
MiR-646 prevents proliferation and progression of human breast cancer cell lines by suppressing HDAC2 expression.
Neoplasms
Modifications of cell signalling and redox balance by targeting protein acetylation using natural and engineered molecules: implications in cancer therapy.
Neoplasms
Modulating chromatin structure and DNA accessibility by deacetylase inhibition enhances the anti-cancer activity of silver nanoparticles.
Neoplasms
Modulation of tumorigenesis by dietary intervention is not mediated by SIRT1 catalytic activity.
Neoplasms
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.
Neoplasms
Neuroblastoma stem cells - mechanisms of chemoresistance and histonedeacetylase inhibitors.
Neoplasms
Nicotinamide-mediated inhibition of SIRT1 deacetylase is associated with the viability of cancer cells exposed to antitumor agents and apoptosis.
Neoplasms
Nuclear import of histone deacetylase 5 by requisite nuclear localization signal phosphorylation.
Neoplasms
O-GlcNAcylation regulates breast cancer metastasis via SIRT1 modulation of FOXM1 pathway.
Neoplasms
Omentin-1, a new adipokine, promotes apoptosis through regulating Sirt1-dependent p53 deacetylation in hepatocellular carcinoma cells.
Neoplasms
Overexpression of HDAC9 promotes oral squamous cell carcinoma growth, regulates cell cycle progression, and inhibits apoptosis.
Neoplasms
Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors.
Neoplasms
Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I.
Neoplasms
Pharmacological activation of SIRT6 triggers lethal autophagy in human cancer cells.
Neoplasms
Potentiation of tumor necrosis factor-induced NF-kappa B activation by deacetylase inhibitors is associated with a delayed cytoplasmic reappearance of I kappa B alpha.
Neoplasms
Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.
Neoplasms
Quercetin 3,5,7,3',4'-pentamethyl ether from Kaempferia parviflora directly and effectively activates human SIRT1.
Neoplasms
RBP1 recruits the mSIN3-histone deacetylase complex to the pocket of retinoblastoma tumor suppressor family proteins found in limited discrete regions of the nucleus at growth arrest.
Neoplasms
Recent progress in understanding the relationships among aging, replicative senescence, cell turnover and cancer.
Neoplasms
Regulation of Apoptosis and Radiation Sensitization in Lung Cancer Cells via the Sirt1/NF-?B/Smac Pathway.
Neoplasms
Regulation of NF-kappaB circuitry by a component of the nucleosome remodeling and deacetylase complex controls inflammatory response homeostasis.
Neoplasms
RelB acts as a molecular switch driving chronic inflammation in glioblastoma multiforme.
Neoplasms
Repression of SIRT1 promotes the differentiation of mouse induced pluripotent stem cells into neural stem cells.
Neoplasms
Resveratrol protects against doxorubicin-induced cardiotoxicity in aged hearts through the SIRT1-USP7 axis.
Neoplasms
Resveratrol-induced Sirt1 phosphorylation by LKB1 mediates mitochondrial metabolism.
Neoplasms
Resveratrol-mediated apoptosis of hodgkin lymphoma cells involves SIRT1 inhibition and FOXO3a hyperacetylation.
Neoplasms
Role of the Sin3-histone deacetylase complex in growth regulation by the candidate tumor suppressor p33(ING1).
Neoplasms
SALL1 functions as a tumor suppressor in breast cancer by regulating cancer cell senescence and metastasis through the NuRD complex.
Neoplasms
Scriptaid overcomes hypoxia-induced cisplatin resistance in both wild-type and mutant p53 lung cancer cells.
Neoplasms
SIRT1 and circadian gene expression in pancreatic ductal adenocarcinoma: Effect of starvation.
Neoplasms
SIRT1 catalytic activity has little effect on tumor formation and metastases in a mouse model of breast cancer.
Neoplasms
SirT1 confers hypoxia-induced radioresistance via the modulation of c-Myc stabilization on hepatoma cells.
Neoplasms
SIRT1 deacetylated and stabilized XRCC1 to promote chemoresistance in lung cancer.
Neoplasms
Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer.
Neoplasms
SIRT1 overexpression decreases cisplatin-induced acetylation of NF-?B p65 subunit and cytotoxicity in renal proximal tubule cells.
Neoplasms
SIRT1 overexpression protects non-small cell lung cancer cells against osteopontin-induced epithelial-mesenchymal transition by suppressing NF-?B signaling.
Neoplasms
SIRT1 regulates N6 -methyladenosine RNA modification in hepatocarcinogenesis by inducing RANBP2-dependent FTO SUMOylation.
Neoplasms
SIRT1 regulates the phosphorylation and degradation of P27 by deacetylating CDK2 to promote T-cell acute lymphoblastic leukemia progression.
Neoplasms
SIRT1 suppresses colorectal cancer metastasis by transcriptional repression of miR-15b-5p.
Neoplasms
SIRT1-ZEB1-positive feedback promotes epithelial-mesenchymal transition process and metastasis of osteosarcoma.
Neoplasms
SIRT2 as a new player in epigenetic programming of keratinocyte differentiation and a candidate tumor suppressor.
Neoplasms
SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing Agents.
Neoplasms
SIRT2 modulates VEGFD-associated lymphangiogenesis by deacetylating EPAS1 in human head and neck cancer.
Neoplasms
SIRT3 deacetylates and promotes degradation of P53 in PTEN-defective non-small cell lung cancer.
Neoplasms
SIRT3 elicited an anti-Warburg effect through HIF1?/PDK1/PDHA1 to inhibit cholangiocarcinoma tumorigenesis.
Neoplasms
Sirt3 Exerts Its Tumor-Suppressive Role by Increasing p53 and Attenuating Response to Estrogen in MCF-7 Cells.
Neoplasms
SIRT3 regulates cell proliferation and apoptosis related to energy metabolism in non-small cell lung cancer cells through deacetylation of NMNAT2.
Neoplasms
Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress.
Neoplasms
SIRT6 overexpression induces massive apoptosis in cancer cells but not in normal cells.
Neoplasms
SIRT6 overexpression potentiates apoptosis evasion in hepatocellular carcinoma via BCL2-associated X protein-dependent apoptotic pathway.
Neoplasms
SIRT6 Suppresses Cancer Stem-like Capacity in Tumors with PI3K Activation Independently of Its Deacetylase Activity.
Neoplasms
SIRT7 modulates the stability and activity of the renal K-Cl cotransporter KCC4 through deacetylation.
Neoplasms
SIRT7 promotes thyroid tumorigenesis through phosphorylation and activation of Akt and p70S6K1 via DBC1/SIRT1 axis.
Neoplasms
Sirtuin 1 Activation Suppresses the Growth of T-lymphoblastic Leukemia Cells by Inhibiting NOTCH and NF-?B Pathways.
Neoplasms
Sirtuin 1 alleviates endoplasmic reticulum stress-mediated apoptosis of intestinal epithelial cells in ulcerative colitis.
Neoplasms
Sirtuin 1 Inhibiting Thiocyanates (S1th)-A New Class of Isotype Selective Inhibitors of NAD+ Dependent Lysine Deacetylases.
Neoplasms
Sirtuin 2 promotes cell stemness and MEK/ERK signaling pathway while reduces chemosensitivity in endometrial cancer.
Neoplasms
Sirtuin 5: a review of structure, known inhibitors and clues for developing new inhibitors.
Neoplasms
Sirtuin 7-mediated deacetylation of WD repeat domain 77 (WDR77) suppresses cancer cell growth by reducing WDR77/PRMT5 transmethylase complex activity.
Neoplasms
Sodium butyrate promotes apoptosis in breast cancer cells through reactive oxygen species (ROS) formation and mitochondrial impairment.
Neoplasms
Structural Insight into the Interactions between Structurally Similar Inhibitors and SIRT6.
Neoplasms
Suberoylanilide hydroxamic acid blocks self-renewal and homotypic aggregation of inflammatory breast cancer spheroids.
Neoplasms
SUMOylation and SUMO-interacting motif (SIM) of metastasis tumor antigen 1 (MTA1) synergistically regulate its transcriptional repressor function.
Neoplasms
Suppression of deacetylase SIRT1 mediates tumor-suppressive NOTCH response and offers a novel treatment option in metastatic Ewing sarcoma.
Neoplasms
Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo.
Neoplasms
Targeting cancer addiction for SALL4 by shifting its transcriptome with a pharmacologic peptide.
Neoplasms
Targeting MTA1/HIF-1? signaling by pterostilbene in combination with histone deacetylase inhibitor attenuates prostate cancer progression.
Neoplasms
The Central Sirtuin 1/p53 Pathway Is Essential for the Orexigenic Action of Ghrelin.
Neoplasms
The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis.
Neoplasms
The deacetylase SIRT6 promotes the repair of UV-induced DNA damage by targeting DDB2.
Neoplasms
The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer.
Neoplasms
The essential role of microsomal deacetylase activity in the metabolic activation, DNA-(deoxyguanosin-8-yl)-2-aminofluorene adduct formation and initiation of liver tumors by N-hydroxy-2-acetylaminofluorene in the livers of infant male B6C3F1 mice.
Neoplasms
The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell death.
Neoplasms
The histone deacetylase inhibitor trichostatin A induces GADD45 gamma expression via Oct and NF-Y binding sites.
Neoplasms
The NAD-dependent deacetylase SIRT2 regulates T cell differentiation involved in tumor immune response.
Neoplasms
The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo.
Neoplasms
The nucleosome remodeling and deacetylase complex has prognostic significance and associates with immune microenvironment in skin cutaneous melanoma.
Neoplasms
The pan-deacetylase inhibitor panobinostat modulates the expression of epithelial-mesenchymal transition markers in hepatocellular carcinoma models.
Neoplasms
The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines.
Neoplasms
The SIRT2 Deacetylase Stabilizes Slug to Control Malignancy of Basal-like Breast Cancer.
Neoplasms
The sirtuins promote Dishevelled-1 scaffolding of TIAM1, Rac activation and cell migration.
Neoplasms
The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene.
Neoplasms
Transcription factor FOXL2 protects granulosa cells from stress and delays cell cycle: role of its regulation by the SIRT1 deacetylase.
Neoplasms
Trichostatin A-induced apoptosis is mediated by Kruppel-like factor 4 in ovarian and lung cancer.
Neoplasms
TSPYL2 is a novel regulator of SIRT1 and p300 activity in response to DNA damage.
Neoplasms
Tumor suppressor SMAR1 mediates cyclin D1 repression by recruitment of the SIN3/histone deacetylase 1 complex.
Neoplasms
Tumoricidal activities of pterostilbene depend upon destabilizing the MTA1-NuRD complex and enhancing P53 acetylation in hepatocellular carcinoma.
Neoplasms
Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex.
Neoplasms
Up-regulation of miR-146b and down-regulation of miR-200b contribute to the cytotoxic effect of Histone deacetylase inhibitors on ras-transformed thyroid cells.
Neoplasms
Vorinostat and metformin sensitize EGFR-TKI resistant NSCLC cells via BIM-dependent apoptosis induction.
Neoplasms
ZBP-89 reduces histone deacetylase 3 by degrading IkappaB in the presence of Pin1.
Neoplasms
[Effects of curcumin on the acetylation of histone H3, P53 and the proliferation of NB4 cells]
Neoplasms
[Histone deacetylase inhibitors cause the TP53-dependent induction of p21/Waf1 in tumor cells carrying mutations in TP53].
Nervous System Diseases
Resveratrol Promotes Recovery of Hearing following Intense Noise Exposure by Enhancing Cochlear SIRT1 Activity.
Neural Tube Defects
High glucose-induced oxidative stress represses sirtuin deacetylase expression and increases histone acetylation leading to neural tube defects.
Neuralgia
SIRT1 alleviates diabetic neuropathic pain by regulating synaptic plasticity of spinal dorsal horn neurons.
Neuralgia
Spinal miR-34a regulates inflammatory pain by targeting SIRT1 in complete Freund's adjuvant mice.
Neuroblastoma
A silver lining for 24-hydroxycholesterol in Alzheimer's disease: The involvement of the neuroprotective enzyme sirtuin 1.
Neuroblastoma
HDAC6 regulates neuroblastoma cell migration and may play a role in the invasion process.
Neurodegenerative Diseases
Catalytic-independent neuroprotection by SIRT1 is mediated through interaction with HDAC1.
Neurodegenerative Diseases
Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors.
Neurodegenerative Diseases
Differential role of SIRT1/MAPK pathway during cerebral ischemia in rats and humans.
Neurodegenerative Diseases
Discovery of New SIRT2 Inhibitors by Utilizing a Consensus Docking/Scoring Strategy and Structure-Activity Relationship Analysis.
Neurodegenerative Diseases
Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases.
Neurodegenerative Diseases
Function of the SIRT3 mitochondrial deacetylase in cellular physiology, cancer, and neurodegenerative disease.
Neurodegenerative Diseases
HDAC6 ?-tubulin deacetylase: A potential therapeutic target in neurodegenerative diseases.
Neurodegenerative Diseases
HDAC6 as a potential therapeutic target for peripheral nerve disorders.
Neurodegenerative Diseases
Integration of the Deacetylase SIRT1 in the Response to Nucleolar Stress: Metabolic Implications for Neurodegenerative Diseases.
Neurodegenerative Diseases
Role of Sirt1 During the Ageing Process: Relevance to Protection of Synapses in the Brain.
Neurodegenerative Diseases
SIRT1 modulates aggregation and toxicity through deacetylation of the androgen receptor in cell models of SBMA.
Neurodegenerative Diseases
Sirt1 overexpression in neurons promotes neurite outgrowth and cell survival through inhibition of the mTOR signaling.
Neurodegenerative Diseases
The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS.
Neuroinflammatory Diseases
Targeting foam cell formation in inflammatory brain diseases by the histone modifier MS-275.
Non-alcoholic Fatty Liver Disease
A new activator of esterase D decreases blood cholesterol level through ESD/JAB1/ABCA1 pathway.
Non-alcoholic Fatty Liver Disease
AAV8-mediated Sirt1 gene transfer to the liver prevents high carbohydrate diet-induced nonalcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Ablation of systemic SIRT1 activity promotes nonalcoholic fatty liver disease by affecting liver-mesenteric adipose tissue fatty acid mobilization.
Non-alcoholic Fatty Liver Disease
Obesity-Linked Phosphorylation of SIRT1 by Casein Kinase 2 Inhibits Its Nuclear Localization and Promotes Fatty Liver.
Non-alcoholic Fatty Liver Disease
Regulation of Mitochondrial Trifunctional Protein Modulates Nonalcoholic Fatty Liver Disease in Mice.
Non-alcoholic Fatty Liver Disease
SIRT1 transcription is decreased in visceral adipose tissue of morbidly obese patients with severe hepatic steatosis.
Obesity
Combinatorial regulation of a signal-dependent activator by phosphorylation and acetylation.
Obesity
Human Carboxylesterase 2 Reverses Obesity-Induced Diacylglycerol Accumulation and Glucose Intolerance.
Obesity
Hypothalamic SIRT1 prevents age-associated weight gain by improving leptin sensitivity in mice.
Obesity
Inhibition of Mitochondrial Calcium Overload by SIRT3 Prevents Obesity- or Age-Related Whitening of Brown Adipose Tissue.
Obesity
NAD+-dependent deacetylase SIRT3 in adipocytes is dispensable for maintaining normal adipose tissue mitochondrial function and whole body metabolism.
Obesity
Non-enzymatic N-acetylation of Lysine Residues by AcetylCoA Often Occurs via a Proximal S-acetylated Thiol Intermediate Sensitive to Glyoxalase II.
Obesity
SIRT1 deacetylase in POMC neurons is required for homeostatic defenses against diet-induced obesity.
Obesity
SIRT6 cooperates with SIRT5 to regulate bovine preadipocyte differentiation and lipid metabolism via the AMPK? signaling pathway.
Optic Atrophy, Autosomal Dominant
Curcumin prevents cisplatin-induced renal alterations in mitochondrial bioenergetics and dynamic.
Optic Atrophy, Autosomal Dominant
Mitochondrial cAMP prevents apoptosis modulating Sirt3 protein level and OPA1 processing in cardiac myoblast cells.
Optic Nerve Diseases
SIRT1 activating compounds reduce oxidative stress and prevent cell death in neuronal cells.
Optic Nerve Diseases
SIRT1 promotes RGC survival and delays loss of function following optic nerve crush.
Optic Neuritis
SIRT1 activating compounds reduce oxidative stress and prevent cell death in neuronal cells.
Optic Neuritis
SIRT1 promotes RGC survival and delays loss of function following optic nerve crush.
Osteoarthritis
Sirtuin-1 (SIRT1) stimulates growth-plate chondrogenesis by attenuating the PERK-eIF-2?-CHOP pathway in the unfolded protein response.
Osteoarthritis
The NAD-Dependent Deacetylase Sirtuin-1 Regulates the Expression of Osteogenic Transcriptional Activator Runt-Related Transcription Factor 2 (Runx2) and Production of Matrix Metalloproteinase (MMP)-13 in Chondrocytes in Osteoarthritis.
Osteosarcoma
Post-translational regulation contributes to the loss of LKB1 expression through SIRT1 deacetylase in osteosarcomas.
Osteosarcoma
[Histone deacetylase inhibits the growth and migration of human osteosarcoma cells].
Ovarian Neoplasms
Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Ovarian Neoplasms
Lysophosphatidic Acid Promotes Epithelial to Mesenchymal Transition in Ovarian Cancer Cells by Repressing SIRT1.
Ovarian Neoplasms
SIRT1 deacetylates KLF4 to activate Claudin-5 transcription in ovarian cancer cells.
Ovarian Neoplasms
SIRT3 participates in glucose metabolism interruption and apoptosis induced by BH3 mimetic S1 in ovarian cancer cells.
Overnutrition
SIRT6 cooperates with SIRT5 to regulate bovine preadipocyte differentiation and lipid metabolism via the AMPK? signaling pathway.
Pancreatic Neoplasms
Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.
Parasitic Diseases
Histone deacetylase enzymes as potential drug targets in cancer and parasitic diseases.
Parkinson Disease
Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors.
Parkinson Disease
Exifone Is a Potent HDAC1 Activator with Neuroprotective Activity in Human Neuronal Models of Neurodegeneration.
Parkinson Disease
Oxidized nicotinamide adenine dinucleotide-dependent mitochondrial deacetylase sirtuin-3 as a potential therapeutic target of Parkinson's disease.
Parkinson Disease
Rotenone affects p53 transcriptional activity and apoptosis via targeting SIRT1 and H3K9 acetylation in SH-SY5Y cells.
Parkinson Disease
Sirtuin 5: a review of structure, known inhibitors and clues for developing new inhibitors.
Parkinson Disease
The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models.
phosphatidate phosphatase deficiency
Lipin1 is required for skeletal muscle development by regulating MEF2c and MyoD expression.
phosphoribosylaminoimidazole carboxylase deficiency
PAICS contributes to gastric carcinogenesis and participates in DNA damage response by interacting with histone deacetylase 1/2.
Pituitary ACTH Hypersecretion
213?Histone Deacetylase Inhibitor Vorinostat Is a Novel, Promising Treatment for Cushing Disease.
Plasmacytoma
Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells.
Pleural Effusion
Suberoylanilide hydroxamic acid blocks self-renewal and homotypic aggregation of inflammatory breast cancer spheroids.
Pneumonia
Abnormal histone acetylase and deacetylase expression and function in lung inflammation.
Pneumonia
Monosaccharide inhibitors targeting carbohydrate esterase family 4 de-N-acetylases.
Polycystic Kidney Diseases
Inhibition of histone deacetylases targets the transcription regulator Id2 to attenuate cystic epithelial cell proliferation.
Polycystic Kidney, Autosomal Dominant
Inhibition of histone deacetylases targets the transcription regulator Id2 to attenuate cystic epithelial cell proliferation.
Polycystic Kidney, Autosomal Dominant
Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo.
Primary Myelofibrosis
A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF).
Prostatic Neoplasms
Adamantanyl-Histone Deacetylase Inhibitor H6CAHA Exhibits Favorable Pharmacokinetics and Augments Prostate Cancer Radiation Sensitivity.
Prostatic Neoplasms
Androgen deprivation-induced elevated nuclear SIRT1 promotes prostate tumor cell survival by reactivation of AR signaling.
Prostatic Neoplasms
Deficient histone acetylation and excessive deacetylase activity as epigenomic marks of prostate cancer cells.
Prostatic Neoplasms
Metastasis-associated protein 1-mediated antitumor and anticancer activity of dietary stilbenes for prostate cancer chemoprevention and therapy.
Prostatic Neoplasms
Sirtuin 5 regulates the proliferation, invasion and migration of prostate cancer cells through acetyl-CoA acetyltransferase 1.
Prostatic Neoplasms
Targeting MTA1/HIF-1? signaling by pterostilbene in combination with histone deacetylase inhibitor attenuates prostate cancer progression.
Prostatic Neoplasms
Transcriptional Repression of SIRT3 Potentiates Mitochondrial Aconitase Activation to Drive Aggressive Prostate Cancer to the Bone.
Proteinuria
Connectivity mapping of a chronic kidney disease progression signature identified lysine deacetylases as novel therapeutic targets.
Protozoan Infections
Histone deacetylase enzymes as potential drug targets in cancer and parasitic diseases.
Psoriasis
Foxp3+ Regulatory T Cells of Psoriasis Patients Easily Differentiate into IL-17A-Producing Cells and Are Found in Lesional Skin.
Psoriasis
Induction of differentiation in psoriatic keratinocytes by propylthiouracil and fructose.
Psoriasis
Inhibiting Protein Kinase Activity of Pyruvate Kinase M2 by SIRT2 Deacetylase Attenuates Psoriasis.
Pulmonary Aspergillosis
The Lysine Deacetylase RpdA Is Essential for Virulence in Aspergillus fumigatus.
Pulmonary Disease, Chronic Obstructive
Shelterin TPP1 Reduction Causes Telomere Attrition and Cellular Senescence via Sirt1 Deacetylase in Chronic Obstructive Pulmonary Disease.
Pulmonary Disease, Chronic Obstructive
SIRT1 Activity in Peripheral Blood Mononuclear Cells Correlates with Altered Lung Function in Patients with Chronic Obstructive Pulmonary Disease.
Pulmonary Disease, Chronic Obstructive
SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in mice.
Pulmonary Disease, Chronic Obstructive
Sirtuin 3 Inhibits Airway Epithelial Mitochondrial Oxidative Stress in Cigarette Smoke-Induced COPD.
Pulmonary Emphysema
SIRT1 redresses tissue inhibitor of matrix metalloproteinase-1/matrix metalloproteinase-9 imbalance in the development of mouse emphysema and human COPD.
Pulmonary Fibrosis
Effects of dynamic changes in histone acetylation and deacetylase activity on pulmonary fibrosis.
Pulmonary Fibrosis
Inhibiting HDAC3 (Histone Deacetylase 3) Aberration and the Resultant Nrf2 (Nuclear Factor Erythroid-Derived 2-Related Factor-2) Repression Mitigates Pulmonary Fibrosis.
Pulmonary Fibrosis
Sirtuin 6 inhibits MWCNTs-induced epithelial-mesenchymal transition in human bronchial epithelial cells via inactivating TGF-?1/Smad2 signaling pathway.
Renal Insufficiency, Chronic
Connectivity mapping of a chronic kidney disease progression signature identified lysine deacetylases as novel therapeutic targets.
Renal Insufficiency, Chronic
HDAC6 Inhibition Promotes Transcription Factor EB Activation and Is Protective in Experimental Kidney Disease.
Reperfusion Injury
Class-Specific Histone/Protein Deacetylase Inhibition Protects Against Renal Ischemia Reperfusion Injury and Fibrosis Formation.
Reperfusion Injury
PPAR? agonist fenofibrate attenuates iron-induced liver injury in mice by modulating the Sirt3 and ?-catenin signaling.
Reperfusion Injury
SIRT3-mediated cardiac remodeling/repair following myocardial infarction.
Retinal Neovascularization
Potential suppression of the high glucose and insulin-induced retinal neovascularization by Sirtuin 3 in the human retinal endothelial cells.
Retinoblastoma
Insights into the association of the nucleosome remodelling and deacetylase (NURD) complex with friend of gata-1 (FOG-1) from the crystal structure of a retinoblastoma associated protein-48 (RBAP48) fog-1 complex.
Retinoblastoma
LINE-1 silencing by retinoblastoma proteins is effected through the nucleosomal and remodeling deacetylase multiprotein complex.
Retinoblastoma
RBP1 recruits the mSIN3-histone deacetylase complex to the pocket of retinoblastoma tumor suppressor family proteins found in limited discrete regions of the nucleus at growth arrest.
Retinoblastoma
Structural Basis of Plant Homeodomain Finger 6 (PHF6) Recognition by the Retinoblastoma Binding Protein 4 (RBBP4) Component of the Nucleosome Remodeling and Deacetylase (NuRD) Complex.
RNA Virus Infections
Regulation of Retinoic Acid Inducible Gene-I (RIG-I) Activation by the Histone Deacetylase 6.
Sarcoma, Ewing
Suppression of deacetylase SIRT1 mediates tumor-suppressive NOTCH response and offers a novel treatment option in metastatic Ewing sarcoma.
Sarcoma, Ewing
The combination of epigenetic drugs SAHA and HCI-2509 synergistically inhibits EWS-FLI1 and tumor growth in Ewing sarcoma.
Seminoma
Deacetylase activity of human tumor cells producing immunosuppressive aminosugars: its possible role in resistance to cell-mediated cytotoxicity.
Seminoma
Estradiol via estrogen receptor beta influences ROS levels through the transcriptional regulation of SIRT3 in human seminoma TCam-2 cells.
Sepsis
SIRT1 inhibition during the hypoinflammatory phenotype of sepsis enhances immunity and improves outcome.
Sepsis
Sirtuin 2 expression levels may predict the progression of sepsis survivors to chronic critical illness.
Silicosis
Acetylated ?-Tubulin Regulated by N-Acetyl-Seryl-Aspartyl-Lysyl-Proline(Ac-SDKP) Exerts the Anti-fibrotic Effect in Rat Lung Fibrosis Induced by Silica.
Spinal Cord Injuries
HDAC8 Inhibition Reduces Lesional Iba-1+ Cell Infiltration after Spinal Cord Injury without Effects on Functional Recovery.
Starvation
Anti-aging molecule, Sirt1: a novel therapeutic target for diabetic nephropathy.
Starvation
Biotin starvation causes mitochondrial protein hyperacetylation and partial rescue by the SIRT3-like deacetylase Hst4p.
Starvation
Dysregulation of the SIRT1/OCT6 Axis Contributes to Environmental Stress-Induced Neural Induction Defects.
Starvation
MFN1 deacetylation activates adaptive mitochondrial fusion and protects metabolically challenged mitochondria.
Starvation
Regulation of Expression of Autophagy Genes by Atg8a-Interacting Partners Sequoia, YL-1, and Sir2 in Drosophila.
Starvation
SIRT1 and circadian gene expression in pancreatic ductal adenocarcinoma: Effect of starvation.
Stomach Neoplasms
Pan-histone deacetylase inhibitor panobinostat sensitizes gastric cancer cells to anthracyclines via induction of CITED2.
Stomach Neoplasms
Regulation of tNOX expression through the ROS-p53-POU3F2 axis contributes to cellular responses against oxaliplatin in human colon cancer cells.
Stomach Neoplasms
SIRT1 is downregulated in gastric cancer and leads to G1-phase arrest via NF-?B/Cyclin D1 signaling.
Stroke
HDAC2 (Histone deacetylase 2): A critical factor in environmental enrichment-mediated stroke recovery.
Stroke
Promotion of Momordica Charantia polysaccharides on neural stem cell proliferation by increasing SIRT1 activity after cerebral ischemia/reperfusion in rats.
Stroke
The Atherosclerosis Risk Variant rs2107595 Mediates Allele-Specific Transcriptional Regulation of HDAC9 via E2F3 and Rb1.
Stroke
Transgenic supplementation of SIRT1 fails to alleviate acute loss of nigrostriatal dopamine neurons and gliosis in a mouse model of MPTP-induced parkinsonism.
Takayasu Arteritis
Takayasu arteritis risk locus in IL6 represses the anti-inflammatory gene GPNMB through chromatin looping and recruiting MEF2-HDAC complex.
Thrombocytopenia
Megakaryocyte lineage development is controlled by modulation of protein acetylation.
Thyroid Carcinoma, Anaplastic
Histone deacetylase inhibitors upregulate Rap1GAP and inhibit Rap activity in thyroid tumor cells.
Thyroid Neoplasms
SIRT7 promotes thyroid tumorigenesis through phosphorylation and activation of Akt and p70S6K1 via DBC1/SIRT1 axis.
Triple Negative Breast Neoplasms
Acetylation of conserved DVL-1 lysines regulates its nuclear translocation and binding to gene promoters in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Combination of sirtuin 3 and hyperoxia diminishes tumorigenic properties of MDA-MB-231 cells.
Triple Negative Breast Neoplasms
Loss of Sirtuin 1 Alters the Secretome of Breast Cancer Cells by Impairing Lysosomal Integrity.
Tuberculosis
Acetylome analysis reveals diverse functions of lysine acetylation in Mycobacterium tuberculosis.
Tuberculosis
An enzyme-initiated Smiles rearrangement enables the development of an assay of MshB, the GlcNAc-Ins deacetylase of mycothiol biosynthesis.
Tuberculosis
Crystal structure of MshB from Mycobacterium tuberculosis, a deacetylase involved in mycothiol biosynthesis.
Tuberculosis
Identity of cofactor bound to mycothiol conjugate amidase (Mca) influenced by expression and purification conditions.
Tuberculosis
Marine sponge derived natural products as inhibitors of mycothiol-S-conjugate amidase.
Tuberculosis
Mycobacterium tuberculosis Rv1096 protein: gene cloning, protein expression, and peptidoglycan deacetylase activity.
Tuberculosis
N-Acetyl-1-D-myo-inosityl-2-amino-2-deoxy-alpha-D-glucopyranoside deacetylase (MshB) is a key enzyme in mycothiol biosynthesis.
Tuberculosis
Reversible acetylation and inactivation of Mycobacterium tuberculosis acetyl-CoA synthetase is dependent on cAMP.
Tuberculosis
The crystal structure of 1-D-myo-inosityl 2-acetamido-2-deoxy-alpha-D-glucopyranoside deacetylase (MshB) from Mycobacterium tuberculosis reveals a zinc hydrolase with a lactate dehydrogenase fold.
udp-3-o-acyl-n-acetylglucosamine deacetylase deficiency
N-acetylglucosamine-6-phosphate deacetylase in hepatocytes, Kupffer cells and sinusoidal endothelial cells from rat liver.
udp-3-o-acyl-n-acetylglucosamine deacetylase deficiency
Stoichiometry of site-specific lysine acetylation in an entire proteome.
Ureteral Obstruction
Prevention of renal interstitial fibrosis via histone deacetylase inhibition in rats with unilateral ureteral obstruction.
Urinary Bladder Neoplasms
Capsaicin attenuates cell migration via SIRT1 targeting and inhibition to enhance cortactin and ?-catenin acetylation in bladder cancer cells.
Uterine Cervical Neoplasms
Isoflurane promotes proliferation of squamous cervical cancer cells through mTOR-histone deacetylase 6 pathway.
Uterine Cervical Neoplasms
Molecular dynamics simulation of complex Histones Deacetylase (HDAC) Class II Homo Sapiens with suberoylanilide hydroxamic acid (SAHA) and its derivatives as inhibitors of cervical cancer.
Uterine Cervical Neoplasms
Oncogenic viral protein HPV E7 up-regulates the SIRT1 longevity protein in human cervical cancer cells.
Vascular Diseases
A Label-free Sirtuin 1 Assay based on Droplet-Electrospray Ionization Mass Spectrometry.
Vitiligo
SIRT3-Dependent Mitochondrial Dynamics Remodeling Contributes to Oxidative Stress-Induced Melanocyte Degeneration in Vitiligo.
Whooping Cough
Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease.
html completed